Alirocumab reduces MACE irrespective of number of metabolic risk factors, but absolute risk reduction increases with the number of metabolic risk factors, in a post-hoc analysis of ODYSSEY OUTCOMES
ACC 2022 A post hoc pooled analysis from the ORION-10 and ORION-11 trials showed that inclisiran, compared with placebo, in addition to statin and/or ezetimibe provided effective and sustained LDL-c lowering in patients with prior MI.
ACC 2022 ACS patients frequently harbor vulnerable plaques in non-infarct related coronary arteries. The PACMAN AMI study investigated to which degree vulnerable plaques can regress and stabilize in patients receiving alirocumab on top of high-intensity statin.
ACC 2022 Treatment with alirocumab, compared with placebo, in addition to high-intensity statin therapy resulted in greater coronary plaque regression, greater cholesterol core reduction and a higher increase of the protective fibrous cap thickness in patients with acute MI.
In a prespecified subgroup analysis of the FOURIER trial, evolocumab reduces MACE and coronary revascularization in patients prior PCI at baseline with consistent reductions in a broad range of lesion types
Although alirocumab reduced LDL-c in patients with or without a history of HF, alirocumab reduced MACE only in patients without HF and not in patients with a history of HF, in an analysis of ODYSSEY OUTCOMES.
AHA 2021 Two phase I studies report the safety and effectiveness of MK-0616, a new oral PCSK9 inhibitor. MK-0616 lowered free PCSK9 in the blood by ≥90% and reduced LDL-c by ~65% after 14 days of treatment, compared to baseline.
Treatment with the PCSK9 inhibitor evolocumab in high CV risk patients reduced the risk of acute arterial events across all vascular territories, as shown in a post hoc analysis of FOURIER.
Real-world evidence shows that the majority of patients do not achieve their LDL-c target goals. Where do we fall short in the need for combination therapy?
An exploratory analysis of FOURIER showed that lowering of LDL-c by evolocumab below 40 mg/dL resulted in continued reduction of MACE in ASCVD patients.
The NHS has made an agreement on a population health management approach in those eligible for the PCSK9 siRNA inclisiran.
ESC 2021 This pooled, post-hoc analysis of ORION-9, -10, and -11 showed that inclisiran significantly reduced LDL-c compared placebo in patients with and without polyvascular disease.